References
diabetic diet, hypoglycemic, diabetic diets, type 2 diabetes mellitus, Diabetic diet
BLOOD, TYPE 2 DIABETES MELLITUS, GROUP B
Schematic representation of the study design. Group A: Diabetic diet prior group. Group B: D-allulose-containing diabetic diet prior group.The flow chart of participant enrollment.Mean glucose level curves for all meals and each meal during the intake period of each diabetic diet group. Blood glycemic variability at 0 (premeal) to 180 min after the meal in all 20 subjects is shown on the basis of isCGM data. The solid line shows glycemic variability with normal diabetic diet intake, and the dotted line shows glycemic variability with D-allulose-containing diabetic diet intake represents a statistically significant difference (* Comparison of AUC, %TIR, %TAR, and %TBR in the blood glucose variability curve. The AUC, TIR, TAR, and TBR from premeal to 180 min postmeal were analyzed. Represents a statistically significant difference (* Comparison of postprandial endogenous insulin secretory capacity. Comparison of postprandial blood glucose and CPR levels after consumption of normal and D-allulose-containing diabetic diets. Represents a statistically significant difference (* Clinical characteristics of the enrolled subjects with type 2 diabetes mellitus and diet composition of study foods. BMI, body mass index; BP, Blood Pressure; HbA1c, hemoglobin A1c; IRI, immunoreactive insulin; CPR, C-Peptide immunoreactivity; UACR, Urine Albumin-to-Creatinine Ratio; LDL, Low Density Lipoprotein; HDL, High Density Lipoprotein; BUN, blood urea nitrogen; Cre, creatinine; eGFR, estimated Glomerular Filtration Rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CVR-R, Coefficient of variation of R-R interval; CAVI, Cardio Ankle Vascular Index; ABI, Ankle Brachial Index; OHAs, oral hypoglycemic agent; GLP-1RA, glucagon-like peptide-1 receptor agonists.Results of patient satisfaction questionnaires in each diabetic diet group.